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1. Introduction
  Flavivirus infections are a significant public health 
problem. The two medically important and closely-related 
members of Flaviviridae family include dengue virus (DV) 
and Japanese encephalitis virus (JEV). In the most areas of 
Asia, DV and JEV co-circulate[1]. In the Indian subcontinent 
and Southeast Asia, they are important causes of human 
disease and mortality. JEV and DV exhibit significant 
serological cross-reactivity, which can complicate 
assessment of the relative burdens of each in co-endemic 
areas and also make the serological diagnosis of both the 
diseases difficult[2-4]. DV (types 1, 2, 3 and 4) typically 
cause dengue fever (DF) and dengue haemorrhagic fever/
dengue shock syndrome (DHF/DSS), while JEV typically 
causes acute encephalitis syndrome. However, it has been 
reported that in some cases, DV causes encephalopathy[5-7], 
while JEV causes an undifferentiated febrile illness[8]. 
As the diagnosis of viral infection on the basis of clinical 
syndromes is not reliable, laboratory diagnosis is essential 
for discrimination between DV and JEV infections, 
especially in endemic areas where both the viruses are co-
circulating. 
  Co-infection with JEV and DV is possible in endemic 
areas, hence, co-positivity for both anti-DV IgM and anti-
JEV IgM antibodies should be investigated to differentiate 
co-infection from cross-reactivity. We have been observing 
the co-positivity of anti-DV and anti-JEV IgM in cases 
with overlapping clinical symptoms of DV infection and 
JEV infection. To provide the evidence of true co-infection, 
we retrospectively tested the samples from these cases and 
analyzed the laboratory data.
Objective: To report high co-positivity of anti-dengue virus (DV) and anti-Japanese encephalitis 
virus (JEV) IgM in an area endemic for both the viruses and to discuss the possibilities of co-
infection. Methods: Serum samples from the patients who presented with fever, suspected 
central nervous system infection and thrombocytopenia, were tested for anti-DV IgM and anti-
JEV IgM antibodies. Conventional reverse transcriptase polymerase chain reaction was done for 
detection of DV RNA and JEV RNA. Results: Of 1 410 patient sera tested for anti-DV and anti-
JEV antibodies, 129 (9.14%) were co-positive for both. This co-positivity was observed only in 
those months when anti-JEV IgM positivity was high. Titers of both anti-DV IgM and anti-JEV 
IgM were high in most of the co-positive cases. Among these 129 co-positive cases, 76 were 
tested by conventional reverse transcriptase polymerase chain reaction for both flaviviruses, of 
which eight cases were co-positive for DV and JEV. Conclusions: Co-infection with more than 
one flavivirus species can occur in hyperendemic areas.
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2. Materials and methods 
  We retrospectively retrieved the clinical samples [serum 
and/or cerebrospinal fluid (CSF)] from the patients who 
presented with a suspected central nervous system infection 
and thrombocytopenia (platelet counts less than 100 000/mL) 
during July 2008 to October 2011. Central nervous system 
infections were suspected in patients with fever and at least 
one of the followings: altered sensorium, focal neurological 
signs, or convulsions. Samples were stored at -70 曟 at 
Grade 1 viral diagnostic laboratory. Relevant clinical and 
demographic data were retrieved from the laboratory records. 
All the serum samples were tested for anti-DV IgM antibody 
by IgM antibody capture ELISA (MAC ELISA) kit from IVD 
Research Inc. and for anti-JEV IgM antibody by MAC-
ELISA kit (JEV-Chex-Xcyton), according to manufacturer’s 
instructions. For anti-DV IgM antibody, samples with optical 
absorbance values ≥0.5 were considered positive, while 
for anti-JEV IgM antibody, samples having a value of ≥100 
ELISA units were considered positive. Convalescent samples 
were not available from patients, since it was a retrospective 
study.
  Selected CSF and serum samples from patients showing 
co-positivity were tested for both DV RNA and JEV RNA. 
Criteria for selection are as follows: duration of illness <7 
days and availability of >250 毺L volume of both serum 
and CSF. Only 76 cases fulfilled our selection criteria. RNA 
was extracted using Trizol (Sigma-Aldrich) according to 
the manufacturer’s recommendations and two-step reverse 
transcriptase polymerase chain reaction (RT-PCR) for 
identification of DV was carried out following the protocol 
of Lanciotti et al[9]. For the detection of JEV RNA, extracted 
RNA samples were amplified using method of Yang et al[10]. 
PCR products were visualized after electrophoresis on 2% 
agarose gel.
3. Results 
  During a period of 3.25 years, total 1 410 cases fitted our 
clinical case definition, of which 423 (30.00%) were positive 
for anti-DV IgM antibody alone, 160 (11.34 %) were positive 
for anti-JEV IgM antibody alone and 129 (9.14%) were 
positive for both anti-DV IgM and anti-JEV IgM antibodies. 
Age wise analysis of anti-DV IgM and anti-JEV IgM 
positivity is detailed in Table 1. Demographic, geographic 
and clinical details of the patients were analyzed in three 
groups: group 1, positive for anti-DV IgM alone; group 2, 
positive for anti-JEV IgM alone; and group 3, positive for 
both anti-DV IgM and anti-JEV IgM. Fever was the most 
common presenting symptom followed by focal neurological 
deficit, altered sensorium, seizures, headache and vomiting. 
A few cases also had haemorrhage, petechial rashes, joint 
pain and breathlessness. For geographical analysis, the 
state of Uttar Pradesh was divided into five zones, that is, 
western, eastern, central, northern and southern, as shown 
in Figure 1.  The detail of demographic, geographical and 
clinical analysis in all the three groups is shown in Table 2. 
There was no significant difference in clinical/demographic 
features of DV/JEV infected/co-infected cases (Table 2). 
 
Central zone                South zone                    North zone
East zone                     West zone
Figure 1. Map of Uttar Pradesh depicting the five zones.
  Cases positive for anti-DV IgM were seen throughout the 
year with a peak in July, September and October, while 
cases positive for anti-JEV IgM were seen only during 
September and October. Highest co-positivity was also seen 
in September (Figure 2). 
Table 1
Age wise distribution of patients positive for both anti-DV IgM and anti-JEV IgM. 
Age group (years) Number of cases tested
Number (Rate, %) of positive cases
Anti-DV IgM alone Anti-JEV IgM alone Anti-DV/JEV IgM
0-1   82   20 (24.39)   2 (2.43)  3 (3.65)
1-5 531 170 (32.01) 48 (9.03) 40 (7.53)
5-15 651 217 (33.33)   75 (11.52)   75 (11.52)
15-25   67     7 (10.44)   14 (10.89)     7 (10.44)
25-50   55     8 (14.54)   11 (20.00)    4 (7.27)
>50   24   1 (4.16)   10 (41.66)    0 (0.00)
Total                  1 410 423 (30.00) 160 (11.34) 129 (9.15)
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Figure 2. Line graph showing anti-DV/JEV IgM positivity during July 
2008-October 2011.
  Results of IgM detection in relation to duration of illness 
are shown in Table 3. Total 278 cases presented with illness 
of <5 days duration, of which 59.89% cases were positive for 
antibody detection, while of 1 132 cases who presented with 
illness of 5 or more days, 12.23% cases were positive. 
  During the study period, 3 168 samples were tested by the 
Grade 1 Viral diagnostic laboratory for anti-DV IgM alone, 
of which 1 506 (47.54%) were positive, and 2 015 samples 
from suspected Japanese encephalitis cases were tested for 
anti-JEV IgM antibody, of which 463 (22.98%) were positive 
(data retrieved from laboratory results. Details not shown). 
The positivity rate for both JEV and DV in these samples was 
comparable to the positivity rate (39.21% and 20.63%) seen in 
the 1 410 study samples. 
  IgM antibody levels of patients co-positive for both anti-
DV and anti-JEV IgM antibodies were plotted on a scatter 
graph (Figure 3). It can be seen that in most of the patients, 
levels of both anti-DV/JEV IgM antibodies were much higher 
than the cut off value. 
Table 2
Characterization of DV/JEV suspected cases.    
Variables
Anti-DV IgM alone positive 
(n=423)*
Anti-JEV IgM alone 
positive (n=160)*
Anti-DV/JEV IgM positive 
(n=129)*
Anti-DV/JEV IgM negative 
(n=698)
Mean age (years)                     7                   14                     8.8     10.8
Sex (Male)                 260                   99                   92                    374
Geographical location
  Eastern UP (n=718)                 215                   85                   74                    344
  Western UP (n=27)                     6                     1                     0                      20
  Northern UP (n=460)                 115                   53                   38                    254
  Southern UP (n=24)                     6                     1                     0                      17
  Central UP (n=181)                   81                   20                   17                      63
Clinical findings
  Fever                 100.00                 100.00                 100.00                 100.00
  Headache 10.38 54.65 44.94 48.95
  Vomiting 39.20 51.78 44.12 54.50
  Joint pain   1.32   0.33   0.82   1.65
  Focal neurological deficit 17.64 65.12 66.45 21.22
  Altered sensorium 41.57 56.23 61.12 45.32
  Breathlessness   1.32   1.65   0.49   5.44
  Seizures 37.96 69.56 66.59 53.96
  Skin rash 24.28   0.99   1.48   6.92
  Haemorrhage 31.81   0.82   0.82   2.41
UP: Uttar Pradesh. *P value of all variables among group was >0.05. 
Table 3
Distribution of DV/JEV suspected cases according to post illness day.
Post illness day (Days) Total number of cases
Number (Rate, %) of positive cases
Anti-DV IgM alone Anti-JEV IgM alone Anti-DV/JEV IgM
≤3 197   9 (4.56)   4 (2.03)   4 (2.03)
4   81     9 (11.11)   3 (3.70)   5 (6.17)
5 141   36 (25.53)   18 (12.77)   15 (10.64)
6   98   47 (47.96)   29 (29.59)   15 (15.31) 
7 154   64 (41.56) 15 (9.74)   27 (17.53)
8 116   74 (63.79)   14 (12.07)   15 (12.93)
9   34   14 (41.18)     8 (23.53)   10 (29.41)
≥10 589 170 (28.86) 103 (17.49) 38 (6.45)
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Figure 3. Scattered graph of DV IgM ELISA optical density (OD) and 
JEV IgM ELISA unit from 129 acute phase patients who were tested 
positive for both anti-DV and anti-JEV IgM antibodies. 
The cut-off value for was 曒0.5, while that for JEV was曒100 ELISA 
unit. 
  Both CSF and sera from 76 cases were tested for both DV/
JEV RNA by conventional RT-PCR. Thirty patients were 
tested positive, eight cases were co-positive for both DV/
JEV RNA (Six in serum only and two in both serum and CSF), 
twelve were positive for DV RNA alone (ten from serum and 
two from CSF), and ten were positive for JEV RNA alone (six 
from serum and four from CSF) (Table 4). No nucleic acid was 
detected from remaining 46 cases. Figure 4 shows the gel 
picture of bands of both DV and JEV RNA in CSF and serum 
of a case co-positive for both anti-DV IgM and anti-JEV 
IgM (case ID: V802). All the DV detected were of serotype 2. 
Of the eight co-positive cases, seven were positive for anti-
DV IgM and seven were positive for anti-JEV IgM, with low 
to moderate values; high values were not seen.
M     1      2       3      4      5
Figure 4. Agarose gel analysis of amplified products from CSF and 
serum samples of a patient positive for both DV and JEV RNA (Case 
ID: V802).
Lane M: 100 bp DNA Ladder (100-1 200 bp); Lane 1: Serum sample 
showing amplified product of 119 bp (positive for DEV serotype 2 
RNA); Lane 2: CSF sample showing amplified product of 119 bp 
(positive for DEV serotype 2 RNA); Lane 3: Serum sample showing 
amplified product of 146 bp (positive for JEV RNA); Lane 4: CSF 
sample showing amplified product of 146 bp (positive for JEV RNA); 
Lane 5: Negative serum sample.
Table 4
RT-PCR results of CSF and serum samples from 76 patients tested 
positive for both anti-JEV and anti-DV IgM.
Sample tested
DV RNA
positive 
JEV RNA 
positive 
DV and JEV 
RNA positive
Serum alone positive 10   6 6
CSF alone positive   2   4 -
Both serum and CSF positive  -  - 2
Total positive 12 10 8
4. Discussion
  DV and JEV are common and phylogenetically related 
flaviruses. Clinical features, seasonality and geographical 
locations for DV and JEV infections overlap. Uttar Pradesh, 
India is a hyperendemic area for both the infections[11,12]. 
Both are mosquito borne illnesses showing the same 
seasonality, and antibodies produced against flavivirus 
infections are known to cross react with each other[13]. JEV 
infection usually manifests as acute encephalitis syndrome 
(AES), while DV infection presents as DF or DHF/DSS. As 
reported earlier in the recent years, a significant proportion 
of children infected with DV in North India presented with 
encephalopathy[14,15]. We observed high co-positivity 
of anti-DV and anti-JEV IgM in sera from the patients 
presenting with features of AES. In a hyperendemic region, 
if a case is positive for both anti-DV IgM and anti-JEV IgM 
antibodies, there are three possibilities: cross-reaction, 
sequential infection and co-infection[16].
  For demonstrating co-infection, (i) either both the 
pathogens should grow in sample, or (ii) nucleic acid of 
both the pathogens should be detected in clinical sample, 
or (iii) rising antibody titre for both the pathogens should be 
demonstrated in paired sera, or (iv) comparing IgM specific 
to DV versus JEV, by measuring neutralizing antibodies[16]. 
Laboratory diagnosis of viral infections is mostly made either 
by serology or by molecular methods[17]. Use of culture for 
diagnosis is limited to very rare situations. Getting paired 
sera for confirming the serological diagnosis is difficult in 
routine clinical settings. Detection of nucleic acid depends 
on post illness day as viral load starts getting lower once 
antibodies start appearing; moreover, viraemia is seen in 
early stages of illness. By the time patient comes to hospital, 
viral load in serum is low[17].
  Our discussion of co-infection vs cross reactivity is based 
on following findings: (a) high antibody titres of both anti-
DV and anti-JEV IgM antibodies, much higher than the 
cut off level, (b) seasonality of co-infection matching to the 
period when both the viruses are detected in population and 
(c) confirmation of co-infection by PCR in patients samples. 
  DV and JEV share antigenic epitopes in the major envelope 
(E) protein, which elicit antibodies commonly referred to as 
cross-reacting antibodies[16,18]. Studies have demonstrated 
that the two viruses can be differentiated by comparing 
the adjusted optical absorbance of anti-DV IgM with that 
of anti-JEV IgM[16,18]. The virus for which titres are high is 
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considered to be the infecting virus[16]. Since high antibody 
titres of both anti-DV and anti-JEV IgM antibodies, much 
higher than the cut off level, were seen in majority of co-
positive patient sera in this study, it is suggested that these 
antibodies were due to DV/JEV co-infection but not to 
cross-reaction secondary to endemicity or immunization as 
reported earlier[13,18]. In a study on 258 confirmed dengue 
cases, 24 (9%) cases had anti-JEV IgM, the levels of anti-
JEV IgM were lower than those of anti-DV IgM and the 
average level of anti-JEV IgM was 19% of that of anti-DV 
IgM[13]. In a study done for identification of Dengue type 
1, 2, 3, Japanese encephalitis and West Nile viruses by 
hemagglutination inhibition test, compliment fixation test 
and neutralization test, serologic responses were found to 
be non-specific[19]. Most often high heterologous titers were 
noted with JEV and West Nile antigens. Traditionally, the 
hemagglutination inhibition assay has been used as gold-
standard serological test, but extensive cross-reaction 
has compromised the general applicability of this assay. 
Similarly, compliment fixation test is not widely used 
currently due to requirement of highly trained personnel 
and cross-reactivity. Plaque reduction and neutralization 
test (PRNT) is the most specific assay for determination of 
DV[20] and JEV[21] neutralizing antibodies and remains the 
ultimate tool for distinguishing between the two viruses. As 
per CDC guidelines, a positive MAC-ELISA result together 
with a virus-specific neutralizing antibody titre by PRNT, 
of more than or equal to 1:4 and >4-fold higher than the 
titre to the other virus is considered positive for that virus; 
a positive or equivocal MAC-ELISA result with a virus-
specific neutralizing titre more than or equal to 1:4 but not 
4-fold higher than the titre to the other virus, is interpreted 
as presumptive; and an equivocal MAC-ELISA result with 
no detectable PRNT titer is considered negative[22]. However, 
this technique has several limitations, such as time-
consuming detection, a long incubation period and labour 
intensive work, and it is therefore recommended for use only 
in reference laboratories with experience in this assay and 
for samples which cannot be easily differentiated by ELISA 
method[21]. For these reasons, ELISA has been proposed as 
a simpler and more rapid alternative[20,21]. The IVD research 
kit for anti-DV IgM (as per the manufacturer) and XCyton kit 
for anti-JEV IgM[23] have reported sensitivities of 100% and 
95% and specificities of 85.9% and 97.5%, respectively.
  In ELISA, IgM antibodies are more specific than IgG[24]. 
When serum samples were tested for IgM and IgG antibodies 
against four Flavivirus antigens, West Nile virus, DV, 
yellow fever virus and tick-borne encephalitis virus, it 
was detected that IgM responses were monotypic, while 
IgG antibodies were cross reactive[24]. Recent studies have 
shown that IgG responses against the pre-membrane protein 
and can distinguish between previous infection with DV and 
JEV[1]. 
  Recent primary DV infection can be confirmed by 
simultaneous presence of IgM and IgA[25] or non-structural 
protein 1 antigen in serum samples. A recent study done on 
fatal dengue meningoencephalitis cases showed that non-
structural protein 1 antigen when used alone had sensitivity 
and specificity of 50% and 100% in CSF, but when used in 
combination with IgM, the detection rate rose to 92.3%[26].
  The pattern of DV infections have changed from seasonal 
to hyperendemic in the Indian continent due to circulation 
of all the four serotypes round the year[27,28], while the JEV 
infections are seasonal occurring mainly in post monsoon 
season[29]. Co-positivity of anti-DV and anti-JEV IgM, 
predominantly in those months when both anti-JEV and 
anti-DV IgM positivity is present in population, is self-
explanatory. Co-positivity in those months when only anti-
DV IgM positivity is present is not observed. A similar trend 
was seen geographically; co-positive cases were seen only 
in areas where both DV and JEV were circulating. 
  The definite proof of current infection of DV or JEV is 
detection of nucleic acid by RT-PCR[20,21], which can be 
detected in blood in approximately the first 5 days of onset 
of symptoms. In this study, RNA of both DV and JEV were 
detected in eight patient samples, two of which were positive 
in both CSF and serum, which confirms co-infection by both 
the viruses. 
  Co-infection of both DV and JEV has also been reported 
previously from the paddy growing Terai regions of Uttar 
Pradesh[11,12] where the environmental conditions are 
very favourable for the mosquito vector. Capability of 
simultaneous multiplication of JEV and DV is also reported 
by Kanthong et al[30] who demonstrated simultaneous co-
infection of JEV, DV and Aedes albopictus densovirus in 
C6/36 mosquito cell lines in laboratory conditions.
  All the DV detected in this study were of serotype 2; it is 
known that patients with DV-2 infections experience more 
severe disease than those infected with other serotypes[31]. 
The clinical implications of co-infection with DV and JEV 
are not well understood. However, a recent study indicates 
that the probability of symptomatic DV-2 illness increases 
due to the prior existence of JEV neutralizing antibodies[32].
The antibodies may not be detectable in clinical samples 
within the first few days of illness. The sensitivity of MAC-
ELISA is approximately 90% when used in samples collected 
after 5 or more days of onset of illness[20,21]. A similar pattern 
was seen in this study.
  This retrospective study has limitations like analysis of 
data is done on the basis of routine records, and all possible 
tests could not be done on all the samples due to limitations 
on volume and availability of desired samples. It is not 
always possible to obtain paired serum sample from patients 
because of several practical reasons: a) late presentation 
of patients to the hospital meaning acute phase sera is not 
available, (b) patient not consenting to give a second blood 
sample, and (c) decline in interest of treating physician, once 
the patient improves. 
  We reported an observation of co-positivity with anti-JEV 
and anti-DV IgM in a hyperendemic area of Northern India. 
This article throws a light on how frequently co-positivity is 
detected in clinical samples from AES cases. 
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